Canaccord Genuity Initiates Coverage On Moderna with Hold Rating, Announces Price Target of $82
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Bill Maughan has initiated coverage on Moderna with a Hold rating and set a price target of $82 for the stock.

November 29, 2023 | 10:16 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity has initiated coverage on Moderna with a Hold rating and a price target of $82, which may influence investor sentiment and stock performance.
The initiation of coverage by Canaccord Genuity with a Hold rating suggests a neutral outlook on Moderna's stock, indicating that the stock is fairly valued at its current price. The price target of $82 provides a benchmark for investors but does not imply significant upside or downside, hence the neutral score. The relevance is high as the news is directly about Moderna. The importance is significant as analyst ratings can impact investor sentiment, but it is not at the highest level as it is a Hold rating rather than a more definitive Buy or Sell. The confidence level is high due to the clear stance taken by the analyst.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100